← Back to Clinical Trials
Recruiting NCT05642897

NCT05642897 Mind Programme for Women With Breast Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05642897
Status Recruiting
Phase
Sponsor University of Coimbra
Condition Breast Cancer Female
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2023-01-02
Primary Completion 2025-05-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
MindSupport Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2023-01-02 with a primary completion date of 2025-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Mind programme for cancer patients was developed by this project PI through the integration of ACT, mindfulness and CFT components specifically adapted to the needs of a cancer population. This intervention aims at improving well-being, preventing subsequent distress, and promoting adaptation to the disease and posttreatment period. A recent pilot study presented preliminary findings on this intervention, suggesting high acceptability and efficacy in improving self-reported psychological health in breast cancer patients undergoing Radiotherapy treatment. Nevertheless, this study's small sample size, methodology (inactive control group), and exclusive reliance on self-reported data limit the interpretation and generalization of results, creating an avenue for the optimization and further testing of the programme through more robust and reliable methods. The aim of this project is therefore to optimize the Mind programme taking into consideration the results from its pilot study and to conduct a Randomized Controlled Trial on the efficacy of the intervention in improving not only mental health outcomes but also biological markers, as well as on its cost-effectiveness, in women with breast cancer. The superiority of the Mind programme will be compared to a support group intervention through the analysis of changes in cancer-specific quality of life, depressive symptoms and anxiety severity, psychological experiences, and immunological and epigenetics markers related to mental health and breast cancer prognosis. All participants will receive the intervention that shows better results.

Eligibility Criteria

Inclusion Criteria: 1. age between 18-70; 2. primary diagnosis of BC (stages between I and III); 3. undergoing radiotherapy treatment at CHUC; 4. able to understand and answer to self-report questionnaires in Portuguese. Exclusion Criteria: 1. currently undergoing any form of psychological intervention; 2. current diagnosis of severe psychiatric illness (psychotic disorder, bipolar disorder, substance abuse, and personality disorder) or suicidal ideation; 3. diagnosis of neurological disease.

Contact & Investigator

Central Contact

Inês A Trindade, PhD

✉ ines.almeidatrindade@gmail.com

📞 239851450

Frequently Asked Questions

Who can join the NCT05642897 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Breast Cancer Female. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05642897 currently recruiting?

Yes, NCT05642897 is actively recruiting participants. Contact the research team at ines.almeidatrindade@gmail.com for enrollment information.

Where is the NCT05642897 trial being conducted?

This trial is being conducted at Coimbra, Portugal.

Who is sponsoring the NCT05642897 clinical trial?

NCT05642897 is sponsored by University of Coimbra. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology